Floatz Rating
CCC53/100
Confidence
Indicative
Sponsor
Masonic Cancer Center, University of Minnesota
Modality
monoclonal_antibody
Development Phase
Phase 2
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
38Indicative
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT06872333CT.gov Allo HSCT for High Risk Hemoglobinopathies | — | Recruiting | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
81High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Transplant Rejection
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Alemtuzumab (this asset) | Masonic Cancer Center, University of Minnesota | P2 | CCC · 53 |
| Busulfanum | Masonic Cancer Center, University of Minnesota | P2 | CCC |
| Cyclophosphamide | Masonic Cancer Center, University of Minnesota | P2 | CCC |
| Sirolimus | Masonic Cancer Center, University of Minnesota | P2 | CCC |
| Anti-Human T-Lymphocyte Immunoglobulin, Rabbit | Masonic Cancer Center, University of Minnesota | P2 | CCC |
| Tacrolimus | Masonic Cancer Center, University of Minnesota | P2 | CCC |
| Fludarabine | Masonic Cancer Center, University of Minnesota | P2 | CCC |
| Plerixafor | Masonic Cancer Center, University of Minnesota | P2 | CCC |
| Ruxolitinib | Arkansas Children's Hospital Research Institute | P1/2 | CC |
+3 more in the Transplant Rejection cohort
Other indications for Alemtuzumab
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Relapsing-Remitting Multiple Sclerosis | — | P4 | BBB · 73 |
| Myelodysplastic/Myeloproliferative Neoplasm | — | P2 | BB · 71 |
| Chronic Myeloid Leukemia | — | P2/3 | BB · 71 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
- BusulfanumMasonic Cancer Center, University of MinnesotaCCC
- CyclophosphamideMasonic Cancer Center, University of MinnesotaCCC
- SirolimusMasonic Cancer Center, University of MinnesotaCCC
- Anti-Human T-Lymphocyte Immunoglobulin, RabbitMasonic Cancer Center, University of MinnesotaCCC
- TacrolimusMasonic Cancer Center, University of MinnesotaCCC
Citation
Floatz Terminal. Alemtuzumab in Transplant Rejection. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/immunoglobulin-g1-human-rat-monoclonal-campath-1h-gamma1-chain-anti-human-antigen-cd52-disulfide-with-human-rat-monoclonal-campath-1h-light-chain-dimer-transplant-rejection
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →